CM
VYNE icon

CM Management’s VYNE Therapeutics VYNE Stock Holding History

CM Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,986
Closed -$200K – 96
2021
Q3 		$200K Hold
7,986
– – 0.15% 88
2021
Q2 		$505K Hold
7,986
– – 0.37% 75
2021
Q1 		$984K Sell
7,986
-961
-11% -$139K 0.73% 59
2020
Q4 		$1.02M Buy
+8,947
New +$1.12M 0.94% 35

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

CM Management's VYNE Position: Q4 2021 in Review

CM Management sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 7,986 shares — an estimated $200K sold.

CM Management first reported a position in VYNE in Q4 2020 and held it in 4 quarters. The position peaked at $1.02M in Q4 2020. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

  • CM Management reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CM Management sold 7,986 VYNE Therapeutics shares in Q4 2021, an estimated $200K.
  • CM Management first reported a position in VYNE Therapeutics in Q4 2020 and held it in 4 quarters.
  • CM Management's VYNE Therapeutics position peaked at $1.02M in Q4 2020.
  • 54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on CM Management's 13F filing for Q4 2021, filed 2 Feb 2022.